Safety and efficacy of azacitidine in myelodysplastic syndromes

被引：25

作者：

Vigil, Carlos E. ^{[1
]}

Martin-Santos, Taida ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2010年 / 4卷

关键词：

Azacitidine; MDS; hypomethylating agents; MYELOID-LEUKEMIA; VALPROIC ACID; 5-AZACYTIDINE; TRANSPLANTATION; EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; METHYLATION; COMBINATION; ANTIGENS; CANCER;

D O I：

10.2147/DDDT.S3143

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.

引用

页码：221 / 229

页数：9

共 50 条

[21] Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes From Study P-2001
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 13
[22] 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
Breccia, Massimo
Loglisci, Giuseppina
Salaroli, Adriano
Serrao, Alessandra
Petrucci, Luigi
Mancini, Marco
Alimena, Giuliana
LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1558 - 1560
[23] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
Garcia, Jacqueline S.
Platzbecker, Uwe
Odenike, Olatoyosi
Fleming, Shaun
Fong, Chun Yew
Cook, Rachel
Jacoby, Meagan
Nowak, Daniel
Chyla, Brenda
Zhou, Ying
Ku, Grace
Potluri, Jalaja
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[24] Systematic Review of the Efficacy and Safety of Alternative Azacitidine Regimens in Myelodysplastic Syndrome
Shapiro, Roman
Iansavichene, Alla
Lazo-Langner, Alejandro
BLOOD, 2015, 126 (23)
[25] Azacitidine in lower-risk myelodysplastic syndromes
Santini, Valeria
LEUKEMIA RESEARCH, 2009, 33 : S22 - S26
[26] An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
Garcia, Jacqueline S.
Jain, Nitin
Godley, Lucy A.
ONCOTARGETS AND THERAPY, 2010, 3 : 1 - 13
[27] AZACITIDINE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE ANALYSIS
Mousinho, F.
Sousa e Santos, P.
Viegas, E.
Madureira, B.
Gomes, A. P.
Falcao, F.
Lima, F.
LEUKEMIA RESEARCH, 2017, 55 : S74 - S74
[28] Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
Musto, Pellegrino
Maurillo, Luca
Spagnoli, Alessandra
Gozzini, Antonella
Rivellini, Flavia
Lunghi, Monia
Villani, Oreste
Aloe-Spiriti, Maria Antonietta
Venditti, Adriano
Santini, Valeria
CANCER, 2010, 116 (06) : 1485 - 1494
[29] Azacitidine adverse effects in patients with myelodysplastic syndromes
San Miguel Amigo L.
Franco Osorio R.
Mercadal Vilchez S.
Martínez-Francés A.
Advances in Therapy, 2011, 28 (Suppl 4) : 6 - 11
[30] Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile
Breccia, Massimo
Voso, Maria Teresa
Maurillo, Luca
Niscola, Pasquale
Fianchi, Luana
Spiriti, Maria Antonietta Aloe
Buccisano, Francesco
Pelliccia, Sabrina
Fenu, Susanna
Tendas, Andrea
Latagliata, Roberto
Alimena, Giuliana
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →